Humacyte, Inc.
HUMA
Biological Products, (No Diagnostic Substances)
Mkt Cap
$810.8MPE
-7.67Debt
$57.96MCash
$115.9MEV
$752.9MFCF
-$83.53MP/E Ratio
-7.67Debt
$57.96MCash
$115.9MEV
$752.9MFCF
-$83.53MCharts data: {"Earnings":[{"time":"2021-12-30","value":-26477000},{"time":"2022-12-30","value":-11965000},{"time":"2023-12-30","value":-110776000}],"Sales":[],"Net Margins":[],"Assets":[{"time":"2021-12-30","value":286533000},{"time":"2022-12-30","value":204302000},{"time":"2023-12-30","value":128223000}],"Stockholders Equity":[{"time":"2021-12-30","value":122174000},{"time":"2022-12-30","value":116928000},{"time":"2023-12-30","value":13546000}],"ROE":[{"time":"2021-12-30","value":-0.21671550411707893},{"time":"2022-12-30","value":-0.10232792829775589},{"time":"2023-12-30","value":-8.177764653772332}],"ROA":[{"time":"2021-12-30","value":-0.2834158718193018},{"time":"2022-12-30","value":-0.41398517880392754},{"time":"2023-12-30","value":-0.7802578320582111}]}
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Sector
In the chart Earnings are multiplied by this value.
Earnings Growth 210%
Earnings Stability -36%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|
| Net Margin | - | - | - | - |
| ROA | -28% | -41% | -78% | -64% |
| ROE | -22% | -10% | -820% | -400% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -49.26%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -24.84%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -283.23%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -398.05%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2021 | 12-2022 | 12-2023 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | -0.42 | -0.51 | -0.69 | ||||||
| Debt Equity | 0.25 | 0.26 | 2.85 | 2.22 | ||||||
| MIN | ||||||||||
| Graham Stability | - | - | - | - | ||||||
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -0.69.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -0.10.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2022 | Trend |
|---|---|---|
| Revenue | - | - |
| Net Income | - | - |
| Stockholders Equity | -88% | -84% |
| FCF | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is -.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is -.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -84.12%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.